Protalix Biotherapeutics, Inc. (PLX)
1.89
-0.02
(-1.05%)
USD |
NYAM |
May 19, 10:05
Protalix Biotherapeutics Research and Development Expense (Quarterly) : 5.426M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Agenus, Inc. | 11.82M |
| Lisata Therapeutics, Inc. | 1.204M |
| Curis, Inc. | 6.449M |
| LadRx Corp. | 0.0288M |
| Plus Therapeutics, Inc. | 2.865M |